Drug Search Results
More Filters [+]

Aflibercept

Alternative Names: aflibercept, ave0005, eylea, vegf trap, zaltrap, ziv-aflibercept
Latest Update: 2024-09-28
Latest Update Note: Clinical Trial Update

Product Description

Aflibercept (EYLEA®), initially named VEGF Trap-eye, is the most recent anti-VEGF agent to be granted US Food and Drug Administration approval for the treatment of neovascular AMD. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4689264/)

Mechanisms of Action: VEGF Antagonist

Novel Mechanism: No

Modality: Fusion Protein

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Algeria | Argentina | Australia | Austria | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Mexico | Netherlands | New Zealand | Norway | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam

Approved Indications: None

Known Adverse Events: None

Company: Regeneron
Company Location: TARRYTOWN NY 10591
Company CEO: Leonard S. Schleifer
Additonal Commercial Interests: Bayer

Clinical Description

Map of Global Clinical Trials for Aflibercept

Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Bulgaria, Canada, China, Colombia, Croatia, Czech Republic, Denmark, Estonia, France, Georgia, Germany, Greece, Hong Kong, Hungary, India, Iran, Israel, Italy, Japan, Korea, Latvia, Lithuania, Malaysia, Mexico, Netherlands, New Zealand, Philippines, Poland, Portugal, Puerto Rico, Romania, Russia, Serbia, Singapore, Slovakia, South Korea, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, Ukraine, United Kingdom, United States, Unknown Location, Vietnam

Active Clinical Trial Count: 67

Highest Development Phases

Phase 3: Choroid Diseases|Dyslipidemia|Glaucoma, Neovascular|Macular Degeneration|Macular Edema|Melanoma|Neovascular age-related macular degeneration|Obstetric Labor, Premature|Other|Retinal Vein Occlusion|Retinopathy of Prematurity|Type 1 Diabetes|Type 2 Diabetes|Wet Macular Degeneration

Phase 2: Colorectal Cancer|Graves Disease|Graves Ophthalmopathy|Retinal Neovascularization|Thyroid Eye Disease|Uveal Melanoma

Phase 1: COVID-19|Malaria

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

MCC-21341

P2

Recruiting

Uveal Melanoma

2030-10-31

BUTTERFLEYE NEXT

P3

Active, not recruiting

Retinopathy of Prematurity

2027-07-19

KILAUEA

P3

Not yet recruiting

Choroid Diseases|Macular Degeneration

2026-09-01

52%

KILAUEA

P3

Not yet recruiting

Choroid Diseases|Macular Degeneration

2026-09-01

52%

PHOTONiC

P3

Recruiting

Macular Edema

2026-05-12

Recent News Events